CU20200097A7 - Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b - Google Patents

Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b

Info

Publication number
CU20200097A7
CU20200097A7 CU2020000097A CU20200097A CU20200097A7 CU 20200097 A7 CU20200097 A7 CU 20200097A7 CU 2020000097 A CU2020000097 A CU 2020000097A CU 20200097 A CU20200097 A CU 20200097A CU 20200097 A7 CU20200097 A7 CU 20200097A7
Authority
CU
Cuba
Prior art keywords
composition
hepatitis
prevent
rinovaccination
obtaining
Prior art date
Application number
CU2020000097A
Other languages
English (en)
Other versions
CU24686B1 (es
Inventor
Rubido Julio Cesar Aguilar
Nieto Gerardo Enrique Guillen
Yoichi Hiasa
Taizou Kamishita
Takashi Miyazaki
Arias Eduardo Penton
Mohammad Fazle Akbar Sheikh
Osamu Yoshida
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma
Univ Nat Corp Ehime Univ
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma, Univ Nat Corp Ehime Univ, Toko Yakuhin Kogyo Kk filed Critical Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma
Publication of CU20200097A7 publication Critical patent/CU20200097A7/es
Publication of CU24686B1 publication Critical patent/CU24686B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/02—Membranes or pistons acting on the contents inside the container, e.g. follower pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a una composición de vacuna contra la hepatitis B, caracterizada porque comprende un antígeno de superficie de la hepatitis B y/o un antígeno de nucleocápside de la hepatitis B, y un material a base de gel que comprende polímero de carboxivinilo. La invención se refiere además a un proceso para preparar dicha composición vacunal y a un sistema de rinovacunación para prevenir y tratar la hepatitis B como se muestra en la figura 1.</p>
CU2020000097A 2018-06-05 2019-06-04 Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b CU24686B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018107797 2018-06-05
PCT/JP2019/022136 WO2019235466A1 (ja) 2018-06-05 2019-06-04 Ｂ型肝炎ワクチン経鼻投与システム

Publications (2)

Publication Number Publication Date
CU20200097A7 true CU20200097A7 (es) 2021-07-02
CU24686B1 CU24686B1 (es) 2023-11-07

Family

ID=68769323

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000097A CU24686B1 (es) 2018-06-05 2019-06-04 Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b

Country Status (15)

Country Link
US (1) US20210187101A1 (es)
EP (1) EP3804752A4 (es)
JP (1) JPWO2019235466A1 (es)
KR (1) KR20210022009A (es)
CN (1) CN112368018A (es)
AU (1) AU2019283122A1 (es)
BR (1) BR112020022784A2 (es)
CA (1) CA3099430A1 (es)
CU (1) CU24686B1 (es)
IL (1) IL278415B2 (es)
MX (1) MX2020013240A (es)
PH (1) PH12020552075A1 (es)
SG (1) SG11202011004RA (es)
TW (1) TW202002950A (es)
WO (1) WO2019235466A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19851282A1 (de) * 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US20090306341A1 (en) 2005-07-29 2009-12-10 Joachim Emmert LC/MS Blends Containing Ionizing Additives
TW201414506A (zh) * 2006-04-21 2014-04-16 Toko Yakuhin Kogyo Kk 噴灑用凝膠型皮膚及／或黏膜附著型製劑及使用該製劑之投藥系統
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
EP2832452B1 (en) 2012-03-30 2017-02-01 Yoshino Kogyosho Co., Ltd. Metered-dose syringe type spray device
JP6322844B2 (ja) * 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
KR102491446B1 (ko) * 2014-06-25 2023-01-20 도코 야쿠힌 고교 가부시키가이샤 인플루엔자 백신의 경비접종 시스템
JP6558392B2 (ja) * 2017-04-04 2019-08-14 ニプロ株式会社 シリンジ型噴出装置

Also Published As

Publication number Publication date
CA3099430A1 (en) 2019-12-12
SG11202011004RA (en) 2020-12-30
JPWO2019235466A1 (ja) 2021-06-24
IL278415B2 (en) 2023-10-01
IL278415B1 (en) 2023-06-01
US20210187101A1 (en) 2021-06-24
EP3804752A1 (en) 2021-04-14
MX2020013240A (es) 2021-05-12
EP3804752A4 (en) 2022-03-09
AU2019283122A1 (en) 2020-11-26
PH12020552075A1 (en) 2021-05-31
CU24686B1 (es) 2023-11-07
KR20210022009A (ko) 2021-03-02
CN112368018A (zh) 2021-02-12
TW202002950A (zh) 2020-01-16
IL278415A (es) 2020-12-31
BR112020022784A2 (pt) 2021-02-02
WO2019235466A1 (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
AR102657A1 (es) Composición para tratar telas
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
MX2018010586A (es) Nanovacuna de activacion de &#34;sting&#34; para inmunoterapia.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112017004393A2 (pt) formulações de anticorpo
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112019024566A2 (pt) inibidores de pirazol magl
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2020004633A (es) Metodo para inactivar el virus de zika y metodos relacionados.
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
MX2019005102A (es) Poxvirus quimericos sinteticos.
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
EA201892003A1 (ru) Лечение атопического дерматита собак
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante